Research in plain language
CJC-1295 + Ipamorelin
This product combines several research peptides. There are no separate studies on the blend itself; below is the published research for each component.
Components
CJC-1295CJC-1295 is a synthetic 30-amino-acid analogue of growth-hormone-releasing hormone (the active hGRH/GRF 1-29 fragment). It binds the pituitary GHRH receptor and makes the gland release growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1). Four amino-acid substitutions protect it from the enzyme dipeptidyl-peptidase-4, so it lasts longer than natural GHRH. Two distinct forms exist and must not be confused. (1) CJC-1295 WITH DAC carries a drug-affinity-complex (a maleimidopropionyl group) that covalently latches onto a free thiol on circulating serum albumin after injection. This stretches its plasma half-life from minutes to roughly 6 to 8 days, giving sustained, non-pulsatile background GH stimulation and once-weekly-style dosing. This is the form used in the published Teichman, Ionescu/Frohman and Alba studies and in the foundational Jette rat work. (2) CJC-1295 WITHOUT DAC is the same modified GRF 1-29 sequence but with no albumin anchor, so it acts short (minutes to about 30 minutes), behaving like sermorelin and producing a single GH pulse. There is no published controlled human trial isolating the no-DAC form; the human evidence below is all for the DAC version. CJC-1295 is not an approved drug, has no established human therapeutic dosing, and is sold for laboratory research only. WADA prohibits it in sport.IpamorelinIpamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) to trigger pulsatile growth hormone (GH) release from the pituitary. It is mainly studied as a selective GH secretagogue and was tested in humans as a ghrelin mimetic to speed gut recovery after bowel surgery.
Study data, research use only. No established human dosing protocol.